Breaking News Instant updates and real-time market news.

ALDR

Alder Biopharmaceuticals

$12.02

-0.66 (-5.21%)

08:10
05/08/19
05/08
08:10
05/08/19
08:10

Alder Biopharmaceuticals presents new analysis in Eptinezumab study at AAN

Alder BioPharmaceuticals announced a new analysis of patient-reported outcomes data from the PROMISE-2 Phase 3 clinical trial of eptinezumab for the prevention of chronic migraine. Eptinezumab is an investigational monoclonal antibody targeting the calcitonin gene-related peptide administered by quarterly infusion for migraine prevention. The new analysis showed improvements in most bothersome migraine symptoms and patients' global impression of change in their migraine status by Month 1 after treatment, with improvements sustained or increased through the first and second quarterly infusion. Detailed data will be presented today at the 71st AAN Annual Meeting in Philadelphia, PA. Highlights from the data analysis include: At Month 1 after treatment: 45% of patients treated with 100 mg of eptinezumab and 57% of patients treated with 300 mg of eptinezumab indicated their MBS was much improved or very much improved vs. 29% of patients receiving placebo; 45% of patients treated with 100 mg of eptinezumab and 59% of patients treated with 300 mg of eptinezumab indicated their PGIC was much improved or very much improved vs. 32% of patients receiving placebo. At Month 6, three months after the second quarterly infusion: 57% of patients treated with 100 mg of eptinezumab and 57% of patients treated with 300 mg of eptinezumab indicated their MBS was much improved or very much improved vs. 42% of patients receiving placebo; 60% of patients treated with 100 mg of eptinezumab and 60% of patients treated with 300 mg of eptinezumab indicated their PGIC was much improved or very much improved vs. 41% of patients receiving placebo.

  • 23

    May

  • 21

    Feb

ALDR Alder Biopharmaceuticals
$12.02

-0.66 (-5.21%)

11/28/18
PIPR
11/28/18
NO CHANGE
Target $28
PIPR
Overweight
Alder Biopharmaceuticals's epti to benefit from SubQ profile, says Piper Jaffray
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $28 price target on Alder Biopharmaceuticals following her meeting with its CEO Robert Azelby. The analyst says that the discussion of the recent launch of competitor SubQ anti-CGRP mAbs for migraine prevention raised the profile of its eptinezumab, noting that "given epti's rapid onset of effect and deep magnitude of response, the company believes there will be demand" for epti. Brill still sees the program's BLA submission on track for Q1 of 2019 with the potential launch coming in Q1 of 2020.
02/25/19
PIPR
02/25/19
NO CHANGE
Target $28
PIPR
Overweight
Piper Jaffray maintains positive view of Alder Biopharmaceuticals' eptinezumab
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $28 price target on Alder Biopharmaceuticals after its Q4 results and update on eptinezumab this evening. The analyst maintains a positive view on the program and contends that "eptinezumab is the best suited agent for the most debilitated migraine patients", adding that the company could generate peak revenues of over $1B if it were to capture just the severe subset of patients.
04/04/19
PIPR
04/04/19
NO CHANGE
PIPR
Overweight
Piper Jaffray stays Overweight on Alder Biopharma, Amgen after Novartis filing
Piper Jaffray analyst Christopher Raymond maintains his Overweight rating on Alder Biopharma (ALDR) and Amgen (AMGN) after the filing by Novartis (NVS) alleging legal dispute with the latter about their migraine collaboration. The analyst says that Novartis tried to beat Amgen to the punch after entering agreement with Alder to manufacture eptinezumab, which prompted Amgen to terminate their commercialization agreement. Raymond adds that a resolution of this dispute could take a year or more but believes that investors may conclude that the spat reflects the value of anti-CGRP assets.
04/18/19
PIPR
04/18/19
NO CHANGE
PIPR
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
Following of survey of 99 neurologists done by his firm's partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly's (LLY) Emgality is lagging and that Teva's Ajovy appears to be gaining ground on Amgen's Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the" lack of clarity regarding when/where EBITDA will hit a trough." On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals' (ALDR) eptinezumab "appears to be particularly top-of-mind among migraine specialists."

TODAY'S FREE FLY STORIES

SWDBY

Swedbank

$0.00

(0.00%)

21:49
07/17/19
07/17
21:49
07/17/19
21:49
Downgrade
Swedbank rating change  »

Swedbank downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULC

Fulcrum Therapeutics

$0.00

(0.00%)

20:53
07/17/19
07/17
20:53
07/17/19
20:53
Syndicate
Fulcrum Therapeutics 4.5M share IPO priced at $16.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

NFLX

Netflix

$362.50

-3.22 (-0.88%)

20:50
07/17/19
07/17
20:50
07/17/19
20:50
Recommendations
Netflix analyst commentary at Pivotal Research »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

PSMT

PriceSmart

$61.77

-0.43 (-0.69%)

20:43
07/17/19
07/17
20:43
07/17/19
20:43
Upgrade
PriceSmart rating change at Scotiabank »

PriceSmart upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMAB

Genmab

$0.00

(0.00%)

20:32
07/17/19
07/17
20:32
07/17/19
20:32
Syndicate
Genmab 28.5M share IPO priced at $17.75 per ADS »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

POWI

Power Integrations

$79.67

-0.22 (-0.28%)

20:29
07/17/19
07/17
20:29
07/17/19
20:29
Upgrade
Power Integrations rating change at Stifel »

Power Integrations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UNH

UnitedHealth

$266.71

2.11 (0.80%)

, HON

Honeywell

$168.81

-6 (-3.43%)

20:25
07/17/19
07/17
20:25
07/17/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

UNH

UnitedHealth

$266.71

2.11 (0.80%)

HON

Honeywell

$168.81

-6 (-3.43%)

PM

Philip Morris

$81.06

-0.49 (-0.60%)

UNP

Union Pacific

$164.05

-11.05 (-6.31%)

DHR

Danaher

$139.60

-0.22 (-0.16%)

MS

Morgan Stanley

$43.78

-0.63 (-1.42%)

BX

Blackstone

$45.27

-0.555 (-1.21%)

BBT

BB&T

$49.68

0.04 (0.08%)

STI

SunTrust

$63.99

0.08 (0.13%)

NUE

Nucor

$54.71

-0.87 (-1.57%)

GPC

Genuine Parts

$102.27

-3.07 (-2.91%)

ALLY

Ally Financial

$31.44

-0.26 (-0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 24

    Jul

  • 06

    Aug

  • 06

    Aug

  • 20

    Aug

  • 21

    Aug

  • 26

    Aug

  • 04

    Sep

  • 05

    Sep

  • 06

    Sep

  • 11

    Sep

  • 26

    Sep

  • 07

    Nov

ADTN

Adtran

$15.84

0.09 (0.57%)

20:07
07/17/19
07/17
20:07
07/17/19
20:07
Earnings
Adtran reports Q2 adjusted EPS 14c, consensus 8c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

BHC

Bausch Health

$22.91

-0.26 (-1.12%)

, PGNX

Progenics

$5.38

0.055 (1.03%)

19:52
07/17/19
07/17
19:52
07/17/19
19:52
Hot Stocks
NJ District Court upholds validity of Relistor patent »

Bausch Health (BHC) and…

BHC

Bausch Health

$22.91

-0.26 (-1.12%)

PGNX

Progenics

$5.38

0.055 (1.03%)

TEVA

Teva

$8.11

-0.07 (-0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 06

    Aug

  • 07

    Aug

  • 09

    Sep

EFC

Ellington Financial

$18.30

0.045 (0.25%)

19:31
07/17/19
07/17
19:31
07/17/19
19:31
Syndicate
Ellington Financial 3.5M share Spot Secondary priced at $17.66 »

Credit Suisse Securities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

EPRT

Essential Properties Realty Trust

$19.83

-0.27 (-1.34%)

19:26
07/17/19
07/17
19:26
07/17/19
19:26
Syndicate
Essential Properties Realty Trust 22.86M share Secondary priced at $19.75 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

FTSV

Forty Seven

$8.77

-1.38 (-13.60%)

19:22
07/17/19
07/17
19:22
07/17/19
19:22
Syndicate
Forty Seven 9.38M share Secondary priced at $8.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 18

    Jul

SNDE

Sundance Energy

$1.67

-0.17 (-9.24%)

19:20
07/17/19
07/17
19:20
07/17/19
19:20
Hot Stocks
Sundance Energy to sell Dimmit County assets for $29.5M »

Sundance Energy Australia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYMT

New York Mortgage

$6.25

-0.01 (-0.16%)

19:18
07/17/19
07/17
19:18
07/17/19
19:18
Syndicate
New York Mortgage 20M share Spot Secondary priced at $6.11 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

IBKC

Iberiabank

$74.44

-0.7 (-0.93%)

18:57
07/17/19
07/17
18:57
07/17/19
18:57
Hot Stocks
Iberiabank raises quarterly dividend by 5% to 45c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 23

    Sep

IBKC

Iberiabank

$74.44

-0.7 (-0.93%)

18:56
07/17/19
07/17
18:56
07/17/19
18:56
Hot Stocks
Iberiabank authorizes 1.6M share repurchase program »

Iberiabank announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 23

    Sep

EBAY

eBay

$39.03

-0.87 (-2.18%)

, LLNW

Limelight Networks

$2.77

0.18 (6.95%)

18:52
07/17/19
07/17
18:52
07/17/19
18:52
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: eBay…

EBAY

eBay

$39.03

-0.87 (-2.18%)

LLNW

Limelight Networks

$2.77

0.18 (6.95%)

NFLX

Netflix

$362.50

-3.22 (-0.88%)

URI

United Rentals

$131.55

-6.05 (-4.40%)

CCK

Crown Holdings

$59.38

-0.88 (-1.46%)

AA

Alcoa

$23.15

-0.18 (-0.77%)

KMI

Kinder Morgan

$20.60

-0.3 (-1.44%)

TCBI

Texas Capital

$58.67

-0.76 (-1.28%)

IBM

IBM

$143.07

-0.47 (-0.33%)

AMRN

Amarin

$21.06

-0.68 (-3.13%)

ROKU

Roku

$109.33

-2.575 (-2.30%)

NYMT

New York Mortgage

$6.25

-0.01 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 07

    Aug

  • 26

    Aug

  • 23

    Sep

  • 28

    Sep

  • 18

    Jul

  • 19

    Jul

NFLX

Netflix

$362.50

-3.22 (-0.88%)

18:42
07/17/19
07/17
18:42
07/17/19
18:42
Hot Stocks
Breaking Hot Stocks news story on Netflix »

Netflix says will add $5B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

MIRM

Mirum Pharmaceuticals

$0.00

(0.00%)

18:42
07/17/19
07/17
18:42
07/17/19
18:42
Syndicate
Mirum Pharmaceuticals 5M share IPO priced at $15.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

GSBC

Great Southern Bancorp

$57.85

-0.78 (-1.33%)

18:31
07/17/19
07/17
18:31
07/17/19
18:31
Earnings
Great Southern Bancorp reports Q2 adjusted EPS $1.28, two estimates $1.15 »

Reports Q2 NII $44.9M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

NFLX

Netflix

$362.50

-3.22 (-0.88%)

18:28
07/17/19
07/17
18:28
07/17/19
18:28
Hot Stocks
Netflix makes 'large investment' in original animation »

Says "Stranger…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

NFLX

Netflix

$362.50

-3.22 (-0.88%)

18:17
07/17/19
07/17
18:17
07/17/19
18:17
Hot Stocks
Netflix says European shows reaching 12M-15M viewers »

Says European shows…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

NFLX

Netflix

$362.50

-3.22 (-0.88%)

18:13
07/17/19
07/17
18:13
07/17/19
18:13
Hot Stocks
Netflix says rate of investment 'extremely high' »

Says has some discretion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

NFLX

Netflix

$362.50

-3.22 (-0.88%)

18:08
07/17/19
07/17
18:08
07/17/19
18:08
Hot Stocks
Netflix says overall additions have returned to normal in Q3 »

Says it's easy to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

IBM

IBM

$143.07

-0.47 (-0.33%)

17:53
07/17/19
07/17
17:53
07/17/19
17:53
Hot Stocks
Breaking Hot Stocks news story on IBM »

IBM pares initial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.